SG1827 / Sumgen Biotech - LARVOL DELTA

CSG-1827-101: An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=122 | Active, not recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Apr 2025 ➔ Jun 2026

Enrollment closed • Trial primary completion date • Solid Tumor

CSG-1827-101: An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=122 | Recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Trial completion date: Mar 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Apr 2025

Trial completion date • Trial primary completion date • Oncology • Solid Tumor

An umbrella trial (RECHALLENGE) to evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumor patients after disease progression in clinical trials. (ESMO-IO 2024) - P1/2 | "Those who progressed on drug A (SG1827, CD80 fusion protein) or B (ABO2011, mRNA vaccine encoding IL-12) will receive their respective drug with Triplimab at 3 mg/kg IV every two weeks, continuing their prior treatment regimen (cohort A, B). Secondary endpoints include efficacy assessments like objective response rate, disease control rate, duration of response, progression-free survival, and overall survival. This trial began in May 2024 and has enrolled 3 patients at the time of submission."

Clinical • Metastases • Oncology • Solid Tumor • CD80 • IL12A

CSG-1827-101: An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=122 | Recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor • IFNG • IL10 • IL6 • TNFA